Infections due to human herpesvirus 6 in solid organ transplant recipients

Current Opinion in Organ Transplantation

Volumn 15, Issue 6, 2010, Pages 671-675

  Razonable, Raymund R ^a,b  

^a Division of Infectious Diseases   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CD3 ANTIBODY; CIDOFOVIR; FOSCARNET; GANCICLOVIR; PENCICLOVIR; VALGANCICLOVIR;

ALLERGIC PNEUMONITIS; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; BONE MARROW SUPPRESSION; COLITIS; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; FEVER; GASTRITIS; GRAFT RECIPIENT; HEPATITIS; HERPES SIMPLEX; HUMAN; HUMAN HERPESVIRUS 6; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; NEUROLOGIC DISEASE; OPPORTUNISTIC INFECTION; ORGAN DONOR; ORGAN TRANSPLANTATION; RASH; REVIEW; SEROPREVALENCE;

ANTIVIRAL AGENTS; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 6, HUMAN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; OPPORTUNISTIC INFECTIONS; ORGAN TRANSPLANTATION; RISK FACTORS;

EID: 78649640599     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e3283404325     Document Type: Review

References (50)

1. Salahuddin SZ, Ablashi DV, Markham PD, et al. Isolation of a new virus, HBLV, in patients with lymphoproliferative disorders. Science 1986; 234:596-601.
2. Yamanishi K, Okuno T, Shiraki K, et al. Identification of human herpesvirus-6 as a causal agent for exanthem subitum. Lancet 1988; 1:1065-1067.
3. Abdel-Massih RC, Razonable RR. Human herpesvirus 6 infections after liver transplantation. World J Gastroenterol 2009; 15:2561-2569.
4. Leong HN, Tuke PW, Tedder RS, et al. The prevalence of chromosomally integrated human herpesvirus 6 genomes in the blood of UK blood donors. J Med Virol 2007; 79:45-51.
5. Tanaka-Taya K, Sashihara J, Kurahashi H, et al. Human herpesvirus 6 (HHV-6) is transmitted from parent to child in an integrated form and characterization of cases with chromosomally integrated HHV-6 DNA. J Med Virol 2004; 73:465-473.
6. De Bolle L, Naesens L, De Clercq E. Update on human herpesvirus 6 biology, clinical features, and therapy. Clin Microbiol Rev 2005; 18:217-245.
7. Razonable RR, Zerr DM. HHV-6, HHV-7, and HHV-8 in solid organ transplant recipients. Am J Transplant 2009; 9:97-103.
8. Feldstein AE, Razonable RR, Boyce TG, et al. Prevalence and clinical significance of human herpesviruses 6 and 7 active infection in pediatric liver transplant patients. Pediatr Transplant 2003; 7:125-129.
9. Cervera C, Marcos MA, Linares L, et al. A prospective survey of human herpesvirus-6 primary infection in solid organ transplant recipients. Transplantation 2006; 82:979-982.
10. Lautenschlager I, Hockerstedt K, Linnavuori K, Taskinen E. Human herpesvirus- 6 infection after liver transplantation. Clin Infect Dis 1998; 26:702-707.
11. Razonable RR, Brown RA, Humar A, et al. Herpesvirus infections in solid organ transplant patients at high risk of primary cytomegalovirus disease. J Infect Dis 2005; 192:1331-1339. (Pubitemid 41401145)
12. Humar A, Kumar D, Caliendo AM, et al. Clinical impact of human herpesvirus 6 infection after liver transplantation. Transplantation 2002; 73:599-604.
13. Lautenschlager I, Linnavuori K, Hockerstedt K. Human herpesvirus-6 antigenemia after liver transplantation. Transplantation 2000; 69:2561-2566.
14. Jacobs U, Ferber J, Klehr HU. Severe allograft dysfunction after OKT3- induced human herpes virus-6 reactivation. Transplant Proc 1994; 26:3121.
15. Peleg AY, Husain S, Kwak EJ, et al. Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody. Clin Infect Dis 2007; 44:204-212.
16. Potenza L, Luppi M, Barozzi P, et al. HHV-6A in syncytial giant-cell hepatitis. N Engl J Med 2008; 359:593-602.
17. Harma M, Hockerstedt K, Krogerus L, Lautenschlager I. Pretransplant human herpesvirus 6 infection of patients with acute liver failure is a risk factor for posttransplant human herpesvirus 6 infection of the liver. Transplantation 2006; 81:367-372.
18. Harma M, Hockerstedt K, Lyytikainen O, Lautenschlager I. HHV-6 and HHV-7 antigenemia related to CMV infection after liver transplantation. J Med Virol 2006; 78:800-805.
19. Razonable RR, Rivero A, Brown RA, et al. Detection of simultaneous betaherpesvirus infections in clinical syndromes due to defined cytomegalovirus infection. Clin Transplant 2003; 17:114-120.
20. Humar A, Asberg A, Kumar D, et al. An assessment of herpesvirus coinfections in patients with CMV disease: correlation with clinical and virologic outcomes. Am J Transplant 2009; 9:374-381.
21. Tiacci E, Luppi M, Barozzi P, et al. Fatal herpesvirus-6 encephalitis in a recipient of a T-cell-depleted peripheral blood stem cell transplant from a 3- loci mismatched related donor. Haematologica 2000; 85:94-97.
22. Zerr DM, Corey L, Kim HW, et al. Clinical outcomes of human herpesvirus 6 reactivation after hematopoietic stem cell transplantation. Clin Infect Dis 2005; 40:932-940.
23. Hoshino K, Nishi T, Adachi H, et al. Human herpesvirus-6 infection in renal allografts: retrospective immunohistochemical study in Japanese recipients. Transpl Int 1995; 8:169-173.
24. Singh N, Carrigan DR, Gayowski T, et al. Variant B human herpesvirus-6 associated febrile dermatosis with thrombocytopenia and encephalopathy in a liver transplant recipient. Transplantation 1995; 60:1355-1357.
25. Randhawa PS, Jenkins FJ, Nalesnik MA, et al. Herpesvirus 6 variant A infection after heart transplantation with giant cell transformation in bile ductular and gastroduodenal epithelium. Am J Surg Pathol 1997; 21:847- 853.
26. Lamoth F, Jayet PY, Aubert JD, et al. Case report: human herpesvirus 6 reactivation associated with colitis in a lung transplant recipient. J Med Virol 2008; 80:1804-1807.
27. Singh N, Carrigan DR, Gayowski T, Marino IR. Human herpesvirus-6 infection in liver transplant recipients: documentation of pathogenicity. Transplantation 1997; 64:674-678.
28. Flamand L, Gosselin J, Stefanescu I, et al. Immunosuppressive effect of human herpesvirus 6 on T-cell functions: suppression of interleukin-2 synthesis and cell proliferation. Blood 1995; 85:1263-1271.
29. Rogers J, Rohal S, Carrigan DR, et al. Human herpesvirus-6 in liver transplant recipients: role in pathogenesis of fungal infections, neurologic complications, and outcome. Transplantation 2000; 69:2566-2573.
30. Emery VC. Human herpesviruses 6 and 7 in solid organ transplant recipients. Clin Infect Dis 2001; 32:1357-1360.
31. Griffiths PD, Ait-Khaled M, Bearcroft CP, et al. Human herpesviruses 6 and 7 as potential pathogens after liver transplant: prospective comparison with the effect of cytomegalovirus. J Med Virol 1999; 59:496-501.
32. Humar A, Kumar D, Raboud J, et al. Interactions between cytomegalovirus, human herpesvirus-6, and the recurrence of hepatitis C after liver transplantation. Am J Transplant 2002; 2:461-466.
33. Lautenschlager I, Lappalainen M, Linnavuori K, et al. CMV infection is usually associated with concurrent HHV-6 and HHV-7 antigenemia in liver transplant patients. J Clin Virol 2002; 25:S57-S61.
34. Lautenschlager I, Linnavuori K, Lappalainen M, et al. HHV-6 reactivation is often associated with CMV infection in liver transplant patients. Transpl Int 2000; 13:S351-S353.
35. Mendez JC, Dockrell DH, Espy MJ, et al. Human beta-herpesvirus interactions in solid organ transplant recipients. J Infect Dis 2001; 183:179-184.
36. Dockrell DH, Mendez JC, Jones M, et al. Human herpesvirus 6 seronegativity before transplantation predicts the occurrence of fungal infection in liver transplant recipients. Transplantation 1999; 67:399-403.
37. Singh N, Husain S, Carrigan DR, et al. Impact of human herpesvirus-6 on the frequency and severity of recurrent hepatitis C virus hepatitis in liver transplant recipients. Clin Transplant 2002; 16:92-96.
38. Chapenko S, Folkmane I, Ziedina I, et al. Association of HHV-6 and HHV-7 reactivation with the development of chronic allograft nephropathy. J Clin Virol 2009; 46:29-32.
39. Neurohr C, Huppmann P, Leuchte H, et al. Human herpesvirus 6 in bronchoalveolar lavage fluid after lung transplantation: a risk factor for bronchiolitis obliterans syndrome? Am J Transplant 2005; 5:2982-2991.
40. Manuel O, Kumar D, Moussa G, et al. Lack of association between betaherpesvirus infection and bronchiolitis obliterans syndrome in lung transplant recipients in the era of antiviral prophylaxis. Transplantation2009; 87:719-725.
41. Ohashi M, Sugata K, Ihira M, et al. Human herpesvirus 6 infection in adult living related liver transplant recipients. Liver Transpl 2008; 14:100-109.
42. Luppi M, Barozzi P, Maiorana A, et al. Human herpesvirus 6 infection in normal human brain tissue. J Infect Dis 1994; 169:943-944.
43. Ogata M, Satou T, Kawano R, et al. Plasma HHV-6 viral load-guided preemptive therapy against HHV-6 encephalopathy after allogeneic stem cell transplantation: a prospective evaluation. Bone Marrow Transplant 2008; 41:279-285.
44. Gautheret-Dejean A, Manichanh C, Thien-Ah-Koon F, et al. Development of a real-time polymerase chain reaction assay for the diagnosis of human herpesvirus- 6 infection and application to bone marrow transplant patients. J Virol Methods 2002; 100:27-35.
45. Clark DA, Nacheva EP, Leong HN, et al. Transmission of integrated human herpesvirus 6 through stem cell transplantation: implications for laboratory diagnosis. J Infect Dis 2006; 193:912-916.
46. Rapaport D, Engelhard D, Tagger G, et al. Antiviral prophylaxis may prevent human herpesvirus-6 reactivation in bone marrow transplant recipients. Transpl Infect Dis 2002; 4:10-16.
47. Tokimasa S, Hara J, Osugi Y, et al. Ganciclovir is effective for prophylaxis and treatment of human herpesvirus-6 in allogeneic stem cell transplantation. Bone Marrow Transplant 2002; 29:595-598.
48. Galarraga MC, Gomez E, de Ona M, et al. Influence of ganciclovir prophylaxis on cytomegalovirus, human herpesvirus 6, and human herpesvirus 7 viremia in renal transplant recipients. Transplant Proc 2005; 37:2124-2126.
49. De Clercq E, Naesens L, De Bolle L, et al. Antiviral agents active against human herpesviruses HHV-6, HHV-7 and HHV-8. Rev Med Virol 2001; 11:381-395.
50. Yoshida M, Yamada M, Tsukazaki T, et al. Comparison of antiviral compounds against human herpesvirus 6 and 7. Antiviral Res 1998; 40:73-84.